Press Release: Medincell: Videoconference and Publication of Half-year Financial Results, Tuesday, December 10th, 2024
Unusual Options Activity: AAL, COIN and Others Attract Market Bets, AAL V/OI Ratio Reaches 75.0
EST Nov 27th Afternoon Delivery - In the last two hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options
Teva to Present at the 7th Annual Evercore ISI HealthCONx Conference
Teva Pharmaceutical (TEVA): The Global Leader in Affordable Medicine Under $25
Goldman's Hedge Fund VIP List: AMZN, VST, CRM, BABA, and More
Unusual Options Activity: TEVA, MDT and Others Attract Market Bets, TEVA V/OI Ratio Reaches 322.6
EST Nov 18th Morning Delivery - In the last two hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends.
Teva Pharmaceutical Industries (NYSE:TEVA) Shareholders Are Still up 85% Over 3 Years Despite Pulling Back 4.0% in the Past Week
US Manufacturing Index Rises To 43, Highest Since 2020
Plant-Based API Market Poised To Hit $52 Billion By 2034, Driven By Psychedelics And Cannabinoids
Unusual Options Activity: CCK, CMG and Others Attract Market Bets, CCK V/OI Ratio Reaches 179.2
EST Nov 15th Morning Delivery - In the last two hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends.
Druckenmiller made significant adjustments in the third quarter: opened positions in Bank of America and Broadcom, continued to increase holdings in the top position Natera.
Natera's position significantly increased by 80.61% compared to the previous quarter. Druckenmiller also established new positions in Broadcom, banks, and pharmaceutical stocks, while completely liquidating News Corp and telecom company Liberty Global, and reducing shareholding in microsoft.
Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory
Druckenmiller's Duquesne Closes Some Media Holdings, Loads Into Regional Banks, Among Q3 Trades
Assertio Stock Gains Amid Clash With Activist Investor, Q3 Earnings
UBS Upgrades Teva Pharmaceutical Industries(TEVA.US) to Buy Rating, Maintains Target Price $26
Teva to Present at the Jefferies London Healthcare Conference
Are Investors Undervaluing Teva Pharmaceutical Industries (TEVA) Right Now?
UBS Downgrades Teva Pharmaceutical Industries(TEVA.US) to Hold Rating, Maintains Target Price $26
BofA Securities Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Raises Target Price to $23
Barclays Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Maintains Target Price $25